Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
In this Phase II trial of personalized immunotherapy in R/M HNSCC, gene expression of LAG3
and CTLA4 by RNA seq will be determined to select the appropriate agent (Ipilimumab or
Relatlimab) to add to Nivolumab in patients with recurrent and/or metastatic squamous cell
carcinoma of the head and neck (R/M HNSCC) who have failed prior immunotherapy with anti-PD-1
or PD-L1 mAb therapy. The agent, either Ipilimumab or Relatlimab will be chosen based on the
highest relevant immune gene expression (CTLA4 or LAG-3) as long as the minimum difference
required is met.